Ajit H Janardhan1, Sarah R Gutbrod2, Wenwen Li2, Di Lang2, Richard B Schuessler3, Igor R Efimov4. 1. Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Biomedical Engineering, Washington University, St. Louis, Missouri. 3. Department of Biomedical Engineering, Washington University, St. Louis, Missouri; Department of Surgery, Cardiothoracic Division, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri; Department of Biomedical Engineering, Washington University, St. Louis, Missouri. Electronic address: igor@wustl.edu.
Abstract
OBJECTIVES: The goal of this study was to develop a low-energy, implantable device-based multistage electrotherapy (MSE) to terminate atrial fibrillation (AF). BACKGROUND: Previous attempts to perform cardioversion of AF by using an implantable device were limited by the pain caused by use of a high-energy single biphasic shock (BPS). METHODS: Transvenous leads were implanted into the right atrium (RA), coronary sinus, and left pulmonary artery of 14 dogs. Self-sustaining AF was induced by 6 ± 2 weeks of high-rate RA pacing. Atrial defibrillation thresholds of standard versus experimental electrotherapies were measured in vivo and studied by using optical imaging in vitro. RESULTS: The mean AF cycle length (CL) in vivo was 112 ± 21 ms (534 beats/min). The impedances of the RA-left pulmonary artery and RA-coronary sinus shock vectors were similar (121 ± 11 Ω vs. 126 ± 9 Ω; p = 0.27). BPS required 1.48 ± 0.91 J (165 ± 34 V) to terminate AF. In contrast, MSE terminated AF with significantly less energy (0.16 ± 0.16 J; p < 0.001) and significantly lower peak voltage (31.1 ± 19.3 V; p < 0.001). In vitro optical imaging studies found that AF was maintained by localized foci originating from pulmonary vein-left atrium interfaces. MSE Stage 1 shocks temporarily disrupted localized foci; MSE Stage 2 entrainment shocks continued to silence the localized foci driving AF; and MSE Stage 3 pacing stimuli enabled consistent RA-left atrium activation until sinus rhythm was restored. CONCLUSIONS: Low-energy MSE significantly reduced the atrial defibrillation thresholds compared with BPS in a canine model of AF. MSE may enable painless, device-based AF therapy.
OBJECTIVES: The goal of this study was to develop a low-energy, implantable device-based multistage electrotherapy (MSE) to terminate atrial fibrillation (AF). BACKGROUND: Previous attempts to perform cardioversion of AF by using an implantable device were limited by the pain caused by use of a high-energy single biphasic shock (BPS). METHODS: Transvenous leads were implanted into the right atrium (RA), coronary sinus, and left pulmonary artery of 14 dogs. Self-sustaining AF was induced by 6 ± 2 weeks of high-rate RA pacing. Atrial defibrillation thresholds of standard versus experimental electrotherapies were measured in vivo and studied by using optical imaging in vitro. RESULTS: The mean AF cycle length (CL) in vivo was 112 ± 21 ms (534 beats/min). The impedances of the RA-left pulmonary artery and RA-coronary sinus shock vectors were similar (121 ± 11 Ω vs. 126 ± 9 Ω; p = 0.27). BPS required 1.48 ± 0.91 J (165 ± 34 V) to terminate AF. In contrast, MSE terminated AF with significantly less energy (0.16 ± 0.16 J; p < 0.001) and significantly lower peak voltage (31.1 ± 19.3 V; p < 0.001). In vitro optical imaging studies found that AF was maintained by localized foci originating from pulmonary vein-left atrium interfaces. MSE Stage 1 shocks temporarily disrupted localized foci; MSE Stage 2 entrainment shocks continued to silence the localized foci driving AF; and MSE Stage 3 pacing stimuli enabled consistent RA-left atrium activation until sinus rhythm was restored. CONCLUSIONS: Low-energy MSE significantly reduced the atrial defibrillation thresholds compared with BPS in a canine model of AF. MSE may enable painless, device-based AF therapy.
Authors: Ajit H Janardhan; Wenwen Li; Vadim V Fedorov; Michael Yeung; Michael J Wallendorf; Richard B Schuessler; Igor R Efimov Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: J Christoph Geller; Sven Reek; Carl Timmermans; Torsten Kayser; Hung Fat Tse; Christian Wolpert; Werner Jung; A John Camm; Chu Pak Lau; Hein J J Wellens; Helmut U Klein Journal: Eur Heart J Date: 2003-12 Impact factor: 29.983
Authors: Ehud J Schmidt; Ronald D Watkins; Menekhem M Zviman; Michael A Guttman; Wei Wang; Henry A Halperin Journal: Circ Cardiovasc Imaging Date: 2016-10 Impact factor: 7.792
Authors: Adam Connolly; Steven Williams; Kawal Rhode; Christopher A Rinaldi; Martin J Bishop Journal: IEEE Trans Biomed Eng Date: 2019-05 Impact factor: 4.538
Authors: Fu Siong Ng; Ondřej Toman; Jan Petru; Petr Peichl; Roger A Winkle; Vivek Y Reddy; Petr Neuzil; R Hardwin Mead; Norman A Qureshi; Zachary I Whinnett; David W Bourn; M Brent Shelton; Josef Kautzner; Arjun D Sharma; Meleze Hocini; Michel Haïssaguerre; Nicholas S Peters; Igor R Efimov Journal: JACC Clin Electrophysiol Date: 2021-03-31
Authors: D Hornung; V N Biktashev; N F Otani; T K Shajahan; T Baig; S Berg; S Han; V I Krinsky; S Luther Journal: R Soc Open Sci Date: 2017-03-15 Impact factor: 2.963